Kodiak Sciences Inc.

Kodiak did not report quarterly revenue, EPS, gross margin, or year-over-year financial results on this business update call. Management said the company had an “attractive cash position” as of Q4 and reiterated a plan to reach meaningful Phase 3/BLA-facing inflections within the current cash runway. Forward-looking operational guidance included: GLOW2 is actively recruiting; DAYBREAK is targeted to start enrollment around mid-2024 after FDA alignment; KSI-101 Phase 1b is planned for the second quarter; and two KSI-101 Phase 2b/3 studies are planned later in 2024. Management also said it is hopeful the completion of two tarcocimab pivotals, the completion of the 501 pivotal, and the 101 studies can fit into the runway into 2026.

Victor Perlroth framed Kodiak as a retina-focused company at a “point of departure,” emphasizing that the next phase is about turning its science into registrational value. He said the company now has three late-phase programs and wants to reach “meaningful Phase 3 BLA facing value inflection points” within the current cash runway. His tone was confident and aspirational, repeatedly stressing durability, the potential of the ABC platform, and the belief that Kodiak can become a major player in retina.

John Borgeson mainly handled the formal setup and risk disclosure rather than discussing a detailed financial model. He confirmed Kodiak had an “attractive cash position” as of Q4, but the call did not include revenue, EPS, margin, or cash-balance figures. Financially, the key message was runway discipline: management said the goal is to advance the three programs to meaningful inflections within existing cash.

Analysts focused on study design, sample size, and whether DAYBREAK would be a large, expensive trial with multiple arms for tarcocimab and KSI-501. Management said the full DAYBREAK design is still being finalized with FDA, that the company is trying to keep it cost-effective, and that the study is intended to generate tarcocimab data for the BLA while also checking the first pivotal box for KSI-501. Questions also probed whether tarcocimab or KSI-501 is the better drug; management declined to rank them and said it would be happy if both succeed. Another concern was what happens if DAYBREAK fails, and management acknowledged it would hurt approval prospects in wet AMD and physician enthusiasm, calling it an “educated gamble.”